Guardant initiates study of its liquid biopsy test

By staff writers

October 5, 2021 -- Precision oncology company Guardant Health has initiated a study to evaluate its Guardant Reveal blood test, a liquid biopsy to predict the recurrence of cancer after curative intent treatment, across 11 solid tumor types.

The observational multicenter study -- Observation of Residual Cancer With Liquid Biopsy Evaluation (ORACLE) -- will enroll 1,000 patients. The study will analyze circulating tumor DNA (ctDNA) levels from blood samples of patients with early-stage cancer using the Guardant Reveal test after the end of treatment and during routine follow-up.

Participants will be followed until distant recurrence (metastasis) or for up to five years. The ORACLE study adds to clinical studies currently underway that are evaluating the performance of the Reveal blood test in patients with early-stage cancer.

Lunit receives $26M funding from Guardant Health
South Korean artificial intelligence (AI) software developer Lunit recently announced a strategic investment of $26 million from Guardant Health....
FDA OKs Guardant liquid biopsy companion test to identify NSCLC
The U.S. Food and Drug Administration (FDA) approved Guardant Health's liquid biopsy companion test to identify patients with nonsmall cell lung cancer...
Natera and Guardant Health embroiled in legal battle
Cell-free DNA testing company Natera and oncology firm Guardant Health have filed dueling false-advertising legal claims over oncology diagnostic tests.
Guardant touts data presented at SABCS
Guardant Health has touted research presented at the 2020 virtual San Antonio Breast Cancer Symposium (SABCS) demonstrating how its tools benefit women...
FDA approves Guardant's liquid biopsy NGS test
The U.S. Food and Drug Administration (FDA) has approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS)...

Copyright © 2021

Last Updated np 10/5/2021 4:42:16 PM